Understanding Advanced Prostate Cancer

Abiraterone And Enzalutamide Effect Cognitive Impairment and Depression in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported [...]

By Malecare|2016-06-14T09:24:42-04:00June 14th, 2016|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, Uncategorized, Understanding Advanced Prostate Cancer, Xtandi, Zytiga|0 Comments

Be Cautious Taking Megace To Treat Hormone Therapy Hot Flashes

When taking hormone therapy (ADT) each of us experiences different side effects and each of us experiences them differently. Anyone experiencing hot flashes, probably the most commonly reported side effect of ADT during hormone therapy (ADT) knows how difficult, embarrassing and uncomfortable they can become as you go through your life. Some men, who find [...]

By Malecare|2017-10-19T10:46:19-04:00June 1st, 2016|ADT, Advanced Prostate Cancer, General Information, Hormone Therapy, Hot Flashes, Side Effects, Uncategorized, Understanding Advanced Prostate Cancer, weight gain|1 Comment

Genetic Biomarker Predicts Peripheral Neuropathy Associated With Docetaxel Chemotherapy For Prostate Cancer

According to researchers at the H. Lee Moffitt Cancer Center & Research Institute, men with a mutation in their VAC14 gene are more susceptible to Docetaxil chemotherapy induced neuropathy and nerve pain. This debilitating side effect results from damage to the peripheral nerves and is felt by the man as weakness, numbness and pain most [...]

By Malecare|2016-05-14T21:37:33-04:00May 14th, 2016|Advanced Prostate Cancer, Chemotherapy, docetaxel, genetics, Pain, peripheral neuropathy, taxotere, Uncategorized, Understanding Advanced Prostate Cancer|2 Comments

An Independent Prognostic Tool For Men With Metastatic Castrate Resistant Prostate Cancer Taking The Newer Drugs

We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]

By Malecare|2020-02-04T11:38:56-05:00May 12th, 2016|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, Drugs & Treatments, enzalutamide, prognostic tools, PSA, Research, Uncategorized, Understanding Advanced Prostate Cancer, Xtandi, Zytiga|1 Comment

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]

By Malecare|2017-10-19T10:46:21-04:00May 11th, 2016|ADT, Advanced Prostate Cancer, Australia, Canada, Clinical Trials, Drugs & Treatments, survival, Survival, Uncategorized, Understanding Advanced Prostate Cancer, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments